The importance of the topic also resides in the oncological syndrome present in CDKN2A mutation carriers, that link melanoma and pancreatic cancer; thus, a CDKN2A-positive individual that has already developed melanoma has a 38-fold increased risk of associating pancreatic malignancies.[7]. Here, CDKN2A is linked to familial pancreatic carcinoma.